Edgestream Partners’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-4,184
| Closed | -$357K | – | 939 |
|
|
2025
Q4 | $357K | Sell |
4,184
-2,965
| -41% | -$243K | 0.01% | 861 |
|
|
2025
Q3 | $556K | Buy |
7,149
+3,454
| +93% | +$270K | 0.02% | 717 |
|
|
2025
Q2 | $289K | Sell |
3,695
-117,875
| -97% | -$8.79M | 0.01% | 789 |
|
|
2025
Q1 | $8.81M | Buy |
+121,570
| New | +$8.7M | 0.3% | 62 |
|
|
2024
Q4 | – | Sell |
-10,294
| Closed | -$679K | – | 927 |
|
|
2024
Q3 | $679K | Buy |
10,294
+5,552
| +117% | +$403K | 0.03% | 645 |
|
|
2024
Q2 | $438K | Buy |
+4,742
| New | +$420K | 0.02% | 689 |
|
|
2023
Q2 | – | Sell |
-12,153
| Closed | -$1.01M | – | 767 |
|
|
2023
Q1 | $1.01M | Sell |
12,153
-10,620
| -47% | -$835K | 0.11% | 295 |
|
|
2022
Q4 | $1.7M | Sell |
22,773
-116,129
| -84% | -$8.95M | 0.19% | 177 |
|
|
2022
Q3 | $11.5M | Buy |
138,902
+97,538
| +236% | +$9.39M | 0.89% | 16 |
|
|
2022
Q2 | $3.93M | Buy |
41,364
+18,379
| +80% | +$1.9M | 0.31% | 102 |
|
|
2022
Q1 | $2.71M | Buy |
+22,985
| New | +$2.58M | 0.22% | 159 |
|
|
2021
Q3 | – | Sell |
-37,127
| Closed | -$3.85M | – | 523 |
|
|
2021
Q2 | $3.85M | Buy |
37,127
+23,979
| +182% | +$2.26M | 0.23% | 152 |
|
|
2021
Q1 | $1.1M | Buy |
13,148
+3,940
| +43% | +$333K | 0.06% | 288 |
|
|
2020
Q4 | $840K | Sell |
9,208
-2,561
| -22% | -$212K | 0.04% | 303 |
|
|
2020
Q3 | $939K | Sell |
11,769
-216,075
| -95% | -$16.9M | 0.06% | 227 |
|
|
2020
Q2 | $15.7M | Buy |
227,844
+91,983
| +68% | +$6.54M | 0.83% | 33 |
|
|
2020
Q1 | $8.54M | Buy |
135,861
+4,815
| +4% | +$347K | 0.79% | 33 |
|
|
2019
Q4 | $10.2M | Sell |
131,046
-3,945
| -3% | -$308K | 0.53% | 57 |
|
|
2019
Q3 | $9.89M | Buy |
134,991
+65,505
| +94% | +$4.6M | 0.95% | 32 |
|
|
2019
Q2 | $4.28M | Buy |
69,486
+32,700
| +89% | +$1.98M | 0.48% | 71 |
|
|
2019
Q1 | $2.35M | Buy |
+36,786
| New | +$2.1M | 0.34% | 89 |
|
|
2018
Q4 | – | Sell |
-64,506
| Closed | -$3.74M | – | 246 |
|
|
2018
Q3 | $3.74M | Sell |
64,506
-50,772
| -44% | -$2.48M | 0.64% | 57 |
|
|
2018
Q2 | $5.59M | Sell |
115,278
-2,544
| -2% | -$119K | 1.14% | 17 |
|
|
2018
Q1 | $5.48M | Buy |
+117,822
| New | +$5.12M | 1.08% | 20 |
|
|
2017
Q4 | – | Sell |
-9,084
| Closed | -$331K | – | 101 |
|
|
2017
Q3 | $331K | Sell |
9,084
-5,634
| -38% | -$215K | 0.18% | 92 |
|
|
2017
Q2 | $580K | Buy |
+14,718
| New | +$537K | 0.22% | 73 |
|
|
2017
Q1 | – | Sell |
-17,982
| Closed | -$562K | – | 141 |
|
|
2016
Q4 | $562K | Sell |
17,982
-73,203
| -80% | -$2.37M | 1.17% | 24 |
|
|
2016
Q3 | $3.66M | Buy |
+91,185
| New | +$3.43M | 2.02% | 10 |
|
|
2016
Q2 | – | Sell |
-38,379
| Closed | -$1.13M | – | 54 |
|
|
2016
Q1 | $1.13M | Buy |
+38,379
| New | +$1.06M | 1.27% | 23 |
|
|
2015
Q4 | – | Sell |
-17,742
| Closed | -$420K | – | 71 |
|
|
2015
Q3 | $420K | Buy |
17,742
+246
| +1% | +$5.94K | 0.73% | 30 |
|
|
2015
Q2 | $415K | Buy |
+17,496
| New | +$395K | 0.29% | 80 |
|
Other funds holding EW
VCM
VPM
Edgestream Partners's EW Position: Q1 2026 in Review
Edgestream Partners sold out of Edwards Lifesciences (EW) in Q1 2026, closing a stake of 4,184 shares — an estimated $357K sold.
Edgestream Partners first reported a position in EW in Q2 2015 and held it in 31 quarters. The position peaked at $15.7M in Q2 2020. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- Edgestream Partners reported no remaining Edwards Lifesciences position as of Q1 2026 after selling out during the quarter.
- Edgestream Partners sold 4,184 Edwards Lifesciences shares in Q1 2026, an estimated $357K.
- Edgestream Partners first reported a position in Edwards Lifesciences in Q2 2015 and held it in 31 quarters.
- Edgestream Partners's Edwards Lifesciences position peaked at $15.7M in Q2 2020.
- 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on Edgestream Partners's 13F filing for Q1 2026, filed 18 May 2026.